Answers are grounded in this paper and cite their sources.
Retrospective analysis develops a scoring system to predict outcomes in untreated metastatic renal cell carcinoma patients treated with Nivolumab and Ipilimumab, suggesting improved patient selection.
Background/Aim: Nivolumab plus ipilimumab (NIVO–IPI) provides durable disease control in a subset of patients with metastatic renal cell carcinoma (mRCC). However, reliable clinical tools for identifying this patient population remain undefined. We aimed to develop a simple clinical score to stratify outcomes in real-world patients treated with first-line NIVO–IPI. Patients and Methods: We conducted a multicenter retrospective analysis of 65 consecutive patients with untreated mRCC who received first-line NIVO–IPI. Progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan–Meier method and Cox proportional hazards model. Based on Cox regression findings and clinical interpretability, a three-factor clinical score was constructed assigning one point each for International Metastatic RCC Database Consortium (IMDC) poor risk (score ≥3), presence of bone metastasis, and elevated baseline C-reactive protein (CRP ≥1 mg/dl). Patients were stratified into three groups (scores 0, 1, and ≥2). Results: Among the 65 patients included, the median PFS and OS were 10.1 and 35.3 months, respectively, and the 12-month PFS and OS rates were 41.9% and 75.5%, respectively. The three-factor score effectively stratified the outcomes. Median PFS was not reached, not reached, and 5.9 months in patients with scores 0, 1, and ≥2, respectively, with corresponding 12-month PFS rates of 72.9, 58.0, and 14.4%. Median OS was not reached, 36.5 months, and 16.8 months, with corresponding 12-month OS rates of 94.4, 92.9, and 54.7%. Conclusion: The developed three-factor clinical score incorporating IMDC risk, bone metastasis, and baseline CRP effectively stratified real-world patients treated with first-line NIVO–IPI. Patients without these risk factors achieved sustained disease control, whereas those with ≥2 risk factors had significantly inferior outcomes. This tool may assist in selecting patients most likely to derive durable benefits from NIVO–IPI in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Yanishi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: